Method for quantitatively detecting single-cell lipidome with high coverage rate

The method improves single-cell lipidomics by using a specific chromatography composition and gradient elution in nano-liquid chromatography-tandem mass spectrometry to enhance lipid detection and reproducibility, achieving high coverage and sensitivity in single-cell lipid analysis.

CN119075383APending Publication Date: 2024-12-06CHANGZHOU ZHONGKE ZHIDIAN BIOTECHNOLOGY CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411070476.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing single-cell lipidomics methods face limitations in lipid coverage and quantitative reproducibility, failing to reliably detect and analyze a broad range of lipids from single cells.

Method used

A method combining nano-liquid chromatography with a specific stationary and mobile phase composition, utilizing a 1:4-2:3 ratio of normal and reverse phase chromatography column fillers, and a mobile phase mixture of chloroform, methanol, ammonia, and ammonium acetate, coupled with nanoliter liquid chromatography-tandem mass spectrometry for gradient elution, to enhance lipid detection and separation.

Benefits of technology

The method achieves high lipid coverage and reproducible detection of up to 312 lipids in single cells, with a median correlation coefficient of 0.91 in large cohort analyses, and sub-femtomolar level quantification using nano-liquid chromatography-tandem mass spectrometry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004980724190000011
    Figure HDA0004980724190000011
  • Figure HDA0004980724190000021
    Figure HDA0004980724190000021
  • Figure HDA0004980724190000031
    Figure HDA0004980724190000031
Patent Text Reader

Abstract

The invention discloses a method for high-coverage quantitative detection of a single-cell lipidome, and belongs to the technical field of analytical chemistry. The technical problem to be solved by the invention is how to improve the lipid coverage rate of single-cell lipid detection and the reliability of a detection result. The invention provides a composition for lipid analysis and a detection method established based on the composition. The composition comprises a nano-liter liquid chromatography stationary phase, the stationary phase comprises normal phase chromatographic column filler and reversed phase chromatographic column filler, and the mass ratio of the normal phase chromatographic column filler to the reversed phase chromatographic column filler is (1: 4)-(2: 3). The detection method established on the basis of the composition can effectively realize the lipid coverage rate of detection of various mixed lipids, and provides a reliable detection result.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the technical field of analytical chemistry, and specifically relates to a method for quantitatively detecting single-cell lipidome with high coverage. Background Art

[0002] Technological breakthroughs in single-cell methodologies have changed the way scientists approach biological problems, from traditional batch detection to quantification of single molecules within single cells. The single-cell revolution in the early branches of omics revealed the ubiquity of cellular heterogeneity in countless biological contexts. Since the pathogenesis of diseases is often attributed to cell-intrinsic and cell-extrinsic alterations, global analysis based on whole tissues may obfuscate subtle intracellular changes and ignore changes in cellular components.

[0003] Single-cell lipidomics provides the closest readout to the actual phenotype, recording the molecular events occurring within the cell with a focus on hydrophobic molecules with less polarity. However, compared to earlier omics, single-cell lipidomics has its own unique technical challenges. For example, high sensitivity is a prerequisite for single-cell lipidomics compared to the signals that can be amplified millions of times in single-cell transcriptomics. The different structural and biochemical roles played by lipids inside and outside the cell make the cellular lipidome dynamic and versatile, which requires extreme care and speed in sampling and processing to accurately reflect the changes of cells in their native state.

[0004] In their early stages of development, single-cell lipidomics approaches have so far focused on maximizing detection. Lipid coverage and reliable structural identification per cell remain limited (typically less than 100 lipids), and quantitative and analytical reproducibility validation of single-cell lipidomics in large cohorts is lacking to date. Summary of the invention

[0005] The technical problem to be solved by this application is: how to improve the lipid coverage of single-cell lipid detection and the reliability of detection results.

[0006] To solve the above technical problems, the present application provides a composition for lipid analysis, which comprises a stationary phase for nano-liquid chromatography, wherein the stationary phase comprises a normal phase chromatography column filler and a reverse phase chromatography column filler, and the mass ratio of the normal phase chromatography column filler to the reverse phase chromatography column filler is 1:4-2:3.

[0007] Furthermore, the composition also includes a mobile phase for nano-liquid chromatography, wherein the mobile phase is a mixture of a mobile phase A and a mobile phase B, wherein the mobile phase A is prepared from chloroform, methanol and aqueous ammonia, and the mobile phase B is prepared from chloroform, methanol, water, aqueous ammonia and ammonium acetate solution.

[0008] Furthermore, in the composition, the mobile phase A is formed by mixing the following raw materials in parts by volume: 890 parts by volume of chloroform, 100 parts by volume of methanol, and 10 parts by volume of aqueous ammonia; the mobile phase B is formed by mixing the following raw materials in parts by volume: 270 parts by volume of chloroform, 650 parts by volume of methanol, 70 parts by volume of water, 10 parts by volume of aqueous ammonia and 2 parts by volume of ammonium acetate solution, wherein the ammonium acetate solution is an aqueous solution with an ammonium acetate content of 1M.

[0009] Furthermore, in the composition, the mobile phase is selected from any one, two or three of the following:

[0010] A1) the mobile phase is mobile phase 2% B, wherein the mobile phase 2% B is a liquid mixed with 98 parts by volume of mobile phase A and 2 parts by volume of mobile phase B;

[0011] A2) the mobile phase is mobile phase 55% B, wherein the mobile phase 55% B is a liquid mixed with 45 parts by volume of mobile phase A and 55 parts by volume of mobile phase B;

[0012] A3) The mobile phase is mobile phase 100% B, and the mobile phase 100% B is 100 parts by volume of mobile phase B.

[0013] The present application also provides a method for lipid analysis, which uses nanoliter liquid chromatography-tandem mass spectrometry to perform lipid analysis. The analysis method includes nanoliter liquid chromatography, and the stationary phase used in the nanoliter liquid chromatography includes normal phase chromatography column filler and reverse phase chromatography column filler. The mass ratio of the normal phase chromatography column filler to the reverse phase chromatography column filler is 1:4-2:3.

[0014] Furthermore, in the method, the nano-liquid chromatography uses the mobile phase for gradient elution, and the flow rate of the mobile phase is 800 nL / min.

[0015] The gradient elution includes the following three steps:

[0016] The first step of elution: elution was performed for 2 minutes using a mobile phase 2% B, wherein the mobile phase 2% B was a liquid mixed with 98 parts by volume of a mobile phase A and 2 parts by volume of a mobile phase B;

[0017] The second step of elution: elution was then performed for 2 minutes using a mobile phase of 55% B, wherein the mobile phase 55% B was a liquid mixed with 45 parts by volume of mobile phase A and 55 parts by volume of mobile phase B;

[0018] The third step of elution: elution was performed again with mobile phase 100% B for 7.5 minutes, wherein the mobile phase 100% B was 100 parts by volume of mobile phase B;

[0019] The mobile phase A is formed by mixing the following raw materials in parts by volume: 890 parts by volume of chloroform, 100 parts by volume of methanol, and 10 parts by volume of aqueous ammonia; the mobile phase B is formed by mixing the following raw materials in parts by volume: 270 parts by volume of chloroform, 650 parts by volume of methanol, 70 parts by volume of water, 10 parts by volume of aqueous ammonia, and 2 parts by volume of ammonium acetate solution, wherein the ammonium acetate solution is an aqueous solution containing 1M ammonium acetate.

[0020] Furthermore, in the method described above, the sample for lipid analysis is from a single cell.

[0021] The present application also provides the use of the composition in preparing a product for single-cell lipidomics analysis.

[0022] The present application also provides application of the composition in single-cell lipidomics analysis.

[0023] The present application also provides application of the method described in single cell lipidomics analysis.

[0024] In some embodiments of the present application, the normal phase chromatography filler is unbonded silica.

[0025] In some embodiments of the present application, the reverse phase chromatography filler is octadecyl bonded silica gel.

[0026] In some embodiments of the present application, the normal phase chromatography filler is of the model: Phenomenex Lunasilica (2), 3 μm, 04A-4162.

[0027] In some embodiments of the present application, the model of the reverse phase chromatography filler is: Sunchrom C18, 3μmm, SP-120-3-ODS-AQ.

[0028] In some embodiments of the present application, the ammonia water is an aqueous solution of ammonia, wherein the mass fraction of ammonia is 30%-33%.

[0029] The 1M ammonium acetate is an ammonium acetate aqueous solution having an ammonium acetate content of 1 mol / L.

[0030] In some embodiments of the present application, the nano-liquid chromatography in nano-liquid chromatography-tandem mass spectrometry includes the steps of eluting and separating lipids, and the steps of eluting and separating lipids include:

[0031] Lipids were eluted and separated by an analytical column (150 μm inner diameter, 6.8 cm length) using a packing material containing a normal phase chromatography filler (Phenomenex Luna silica (2), 5 μm, 04A-4274). Mobile phase A consisted of chloroform: methanol: ammonia (890: 100: 10, v / v / v), and mobile phase B consisted of chloroform: methanol: water: ammonia: 1 M ammonium acetate (270: 650: 70: 10: 2, v / v / v / v). The flow rate was 800 nL / min, and the total duration of the nano-LC method was 13 minutes. The gradient started at 2% B for 2 minutes, increased to 55% B at the 3rd minute and maintained for 1 minute, and then further increased to 100% B at the 5th minute. The gradient was maintained at 100% B for 7.5 minutes, then dropped back to 2% B after 0.4 minutes, and equilibrated for 0.1 minutes before the next injection.

[0032] The mass spectrometry source parameters used in the nano-liquid chromatography-tandem mass spectrometry are as follows: Curtain gas = 30, Collision gas = High, Ion Spray Voltage = 2400V, Ion Source Gas 1 = 5. Lipids are identified based on accurate retention time (Rts) and characteristic product fragments.

[0033] In some embodiments of the present application, the internal standard method is used for determination, and the internal standard mixture used in the internal standard method is composed of d9-phosphatidylcholine (2 ng / mL, Avanti 860352P), d7-phosphatidylethanolamine (1 ng / mL, Avanti 791638C), d7-phosphatidylglycerol (1 ng / mL, Avanti 791640C), d7-phosphatidylinositol (0.5 ng / mL, Avanti791641C), d9-phosphatidylcholine (1 ng / mL, Avanti 852475C), d9-sphingomyelin (1 ng / mL, Avanti791649C), d7-ceramide (5 ng / mL, Avanti 860681P), C8-glucosylceramide (2 ng / mL, Avanti 860540P), d3-lactosylceramide (2 ng / mL, Matreya LLC 1534), trihexosylceramide (1 ng / mL, Matreya LLC 1523), d7-lysophosphatidylcholine (5 ng / mL, Avanti 791643C), d7-lysophosphatidylethanolamine (5 ng / mL, Avanti 791644C), C17:1-lysophosphatidylinositol (0.5 ng / mL, Avanti 850103P), d6-cholesterol ester (6 μg / mL, CDN Isotopes D5823), d5-triglyceride (0.1 μg / mL, CDN Isotopes D6958), d5-diaceryl (0.05 μg / mL, Avanti 110538), d5-diaceryl (0.04 μg / mL, Avanti 110581), d3-carnitine (0.6 ng / mL Cambridge Isotopes Laboratory DLM-1263) was dissolved in a solvent. The solvent was a mixture of methanol: acetonitrile (Honeywell LC015-4): water: 1M ammonium acetate in a volume ratio of 450:450:100:2.

[0034] In some embodiments of the present application, the sample for lipid analysis is from a single cell.

[0035] In some embodiments of the present application, the method for extracting lipids from the single cell comprises:

[0036] S1) Cells were sorted using a 130 μm nozzle on a flow cytometer. Single cells were sorted into 2 mL glass vials, each containing 1 mL of LCMS grade methanol (Fisher chemical A456-4) to immediately quench the cells for further biological activity. After cell sorting, the cells in methanol were briefly centrifuged and then immediately frozen at -80 °C until lipid extraction.

[0037] S2) 333 μL of ice-cold chloroform (CNWTechnologies CAEQ-4-011024-4000) and 148 μL of water (Fisher chemical W6-4) were added to a single cardiomyocyte in 1 mL of LCMS-grade methanol. The sample was incubated at 1500 rpm for 30 min at 4°C and then centrifuged at 4200 rpm for 10 min at 4°C. The clean supernatant was transferred to a fresh glass vial and dried using a SpeedVac vacuum concentrator in the mid-OH mode. The dried lipid extract in the 2 mL glass vial was thoroughly resuspended in 150 μL of chloroform: methanol (1:1, v / v), carefully transferred to a glass insert (Agilent 5181-1270), and dried again using a SpeedVac vacuum concentrator in the mid-OH mode to obtain a concentrated lipid extract.

[0038] The concentrated lipid extract was resuspended in 15 μL of internal standard mix and centrifuged briefly to remove air bubbles before analysis.

[0039] In some embodiments of the present application, the method further comprises using a QC sample for quality control, wherein the QC sample is obtained by dissolving a lipid concentrate extracted from N single cells in a 15×N μL internal standard mixture and then dividing into N equal parts, 50≤N≤200;

[0040] The quality control is achieved by measuring the accuracy of the results of QC samples randomly added between the samples to be tested.

[0041] In some embodiments of the present application, the QC samples are randomly added between the samples to be tested, and the reliability of the test results of the samples to be tested is judged based on the accuracy of the test results of the QC samples. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 Figure 2. Triangular correlation matrix of QC samples in a batch analysis of 544 individual cardiomyocytes.

[0043] Figure 2 The internal standard calibration curve.

[0044] Figure 3 This is the lipid subclass separation result when the mass ratio of normal phase chromatography column filler to reverse phase chromatography column filler is 1:4.

[0045] Figure 4 This is the lipid subclass separation result when the mass ratio of normal phase chromatography column filler to reverse phase chromatography column filler is 3:7.

[0046] Figure 5This is the lipid subclass separation result when the mass ratio of normal phase chromatography column filler to reverse phase chromatography column filler is 2:3. DETAILED DESCRIPTION

[0047] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0048] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0049] Embodiment 1, method flow

[0050] 1.1. Flow cytometry sorting of single mouse cardiomyocytes

[0051] Cell sorting was performed on a BD FACS Aria Fusion flow cytometer using a 130 μm nozzle. Single cells were sorted into 2 mL glass vials, each containing 1 mL of LCMS grade methanol (Fisher chemical A456-4) for immediate quenching of further biological activity of the cells. After cell sorting, the cells in methanol were briefly centrifuged and then immediately frozen at -80 °C until lipid extraction.

[0052] 1.2 Single-cell lipidomics

[0053] 333 μL of ice-cold chloroform (CNW Technologies CAEQ-4-011024-4000) and 148 μL of water (Fisher chemical W6-4) were added to a single cardiomyocyte in 1 mL of LCMS-grade methanol. The samples were incubated at 1500 rpm for 30 min at 4°C and then centrifuged at 4200 rpm for 10 min at 4°C. The clean supernatant was transferred to a fresh glass vial and dried using a SpeedVac vacuum concentrator in the mid-OH mode. The dried lipid extract in the 2 mL glass vial was thoroughly resuspended in 150 μL of chloroform:methanol (1:1, v / v), carefully transferred to a glass insert (Agilent 5181-1270), and dried again using a SpeedVac vacuum concentrator in the mid-OH mode to obtain a concentrated lipid extract. The concentrated lipid extract was resuspended in 15 μL of the internal standard mixture and briefly centrifuged to remove bubbles before analysis. The internal standard mixture consisted of d9-phosphatidylcholine (final concentration in the internal standard mixture was 2 ng / mL (the concentrations of other internal standard substances were the same as the final concentrations), Avanti 860352P), d7-phosphatidylethanolamine (1 ng / mL, Avanti 791638C), d7-phosphatidylglycerol (1 ng / mL, Avanti 791640C), d7-phosphatidylinositol (0.5 ng / mL, Avanti 791641C), d9-phosphatidylcholine (1 ng / mL, Avanti 852475C), d9-sphingomyelin (1 ng / mL, Avanti 791649C), d7-ceramide (5 ng / mL, Avanti 860681P), C8-glucosylceramide (2 ng / mL, Avanti 860540P), d3-lactosylceramide (2 ng / mL, Matreya LLC1534), trihexosylceramide (1 ng / mL, Matreya LLC 1523), d7-lysophosphatidylcholine (5 ng / mL, Avanti791643C), d7-lysophosphatidylethanolamine (5 ng / mL, Avanti 791644C), C17:1-lysophosphatidylinositol (0.5 ng / mL, Avanti 850103P), d6-cholesterol ester (6 μg / mL, CDN Isotopes D5823), d5-triglyceride (0.1 μg / mL, CDN Isotopes D6958), d5-diaceryl (0.05 μg / mL, Avanti110538), d5-triglyceride (0.04 μg / mL, Avanti 110581), d3-carnitine (0.6 ng / mL Cambridge Isotopes Laboratory DLM-1263) was dissolved in the solvent.The solvent was methanol:acetonitrile (Honeywell LC015-4):water:1M ammonium acetate (450:450:100:2, v / v / v / v).

[0054] Lipids were analyzed in positive ion mode on a 6500Plus QTRAP (Sciex) coupled to an ekspert nano LC 400 (Eksignent Technologies) using a nano-electrospray ionization source (nano-ESI). For sample loading, the flow rate of loading buffer (methanol:acetonitrile:water:1M ammonium acetate 400:400:200:2, v / v / v / v) was set at 3.3 μL / min for 3 minutes, and 8 μL of sample was injected and captured by a trapping column (200 μm inner diameter, 2 cm length), the filling material consisting of a normal phase chromatography filler (Phenomenex Luna silica (2), 3 μm, 04A-4162) and a reverse phase chromatography filler (Sunchrom C18, 3 μmm, SP-120-3-ODS-AQ) mixed in a ratio of 3:7. After capture, lipids were eluted and separated through an analytical column (150 μm inner diameter, 6.8 cm length) using a packing material comprising a normal phase chromatography packing (Phenomenex Luna silica (2), 5 μm, 04A-4274).

[0055] Mobile phase A consisted of chloroform:methanol:ammonia (890:100:10, v / v / v) and mobile phase B consisted of chloroform:methanol:water:ammonia:1M ammonium acetate (270:650:70:10:2, v / v / v / v). The flow rate was 800 nL / min and the total duration of the nano-LC method was 13 min. The gradient started at 2% B for 2 min, increased to 55% B at 3 min and held for 1 min, and then further increased to 100% B at 5 min. The gradient was maintained at 100% B for 7.5 min, then dropped back to 2% B after 0.4 min and equilibrated for 0.1 min before the next injection. QC samples were 15 μL aliquots prepared from lipid extracts of 100 cell samples on day 0 dissolved in 1.5 mL of internal standard mixture. Source parameters were as follows: Curtain gas = 30, Collision gas = High, Ion Spray Voltage = 2400 V, Ion Source Gas 1 = 5. Lipids were identified based on precise retention times (Rts) and characteristic product fragments and quantified by peak area normalized to the corresponding internal standard from the same lipid class.

[0056] Among them: mobile phase 2% B is a liquid mixed by 98 volume parts of mobile phase A and 2 volume parts of mobile phase B; mobile phase 55% B is a liquid mixed by 45 volume parts of mobile phase A and 55 volume parts of mobile phase B; mobile phase 100% B is 100 volume parts of mobile phase B.

[0057] Time (min) Flow rate (nL / min) Mobile phase A (volume percentage, %) Mobile phase B (volume percentage, %) 0<t≤2 800 98 2 2<t≤3 800 Up to 45 Up to 55 3<t≤4 800 45 55 4<t≤5 800 to 0 Up to 100 5<t≤12.5 800 0 100 12.5<t≤12.9 800 to 98 to 2 12.9<t≤13 800 98 2

[0058] 1.3. Measurement results

[0059] The method utilizes an innovative combination of normal phase chromatography packing (non-bonded silica) and reversed phase chromatography packing (octadecyl bonded silica) as the stationary phase in a hybrid trapping column to effectively pre-concentrate endogenous lipid classes with a broad polarity spectrum, from non-polar neutral lipids to polar lysophospholipids and acylcarnitines.

[0060] Normal phase liquid chromatography-multiple reaction monitoring (NP-LC-MRM) was used for lipid separation, and ammonium acetate was added as a modifier to improve the ionization efficiency of neutral lipids, thereby maximizing lipid coverage within a single injection.

[0061] The method reliably detected 312 lipids in single mouse cardiomyocytes and also showed satisfactory reproducibility in a large cohort analysis of more than 500 injections, as evidenced by the high fit (median correlation coefficient = 0.91) of lipid profiles between quality control (QC) samples inserted throughout the batch ( Figure 1 ).

[0062] One QC sample was injected for every 18 biological samples of individual cardiomyocytes, for a total of 39 QC samples injected and processed throughout the MS run. QC samples were prepared by preparing identical aliquots from lipid extracts of 100 cardiomyocyte samples. The high correlation observed between QC samples demonstrated the reproducibility and consistency of the MS run, with a median correlation coefficient of 0.91. QC: quality control; MS: mass spectrometry.

[0063] Example 2, determination of LOD and LOQ

[0064] The endogenous concentrations of each lipid class within a single cardiomyocyte were estimated from preliminary experiments, and the internal standard concentrations used for quantification were adjusted so that the internal standard concentrations fell within the concentration range of endogenous substances within the same lipid class. The resulting internal standard mixture was used to construct a calibration curve. A series of dilutions of the internal standard mixture was prepared with an initial concentration of 10 times the quantification internal standard concentration, diluted 3 times in sequence, and injected into the MS, containing a total of 10 concentrations. The peak area of ​​the internal standard was plotted versus the concentration. Linear regression was used to calculate the r of the calibration curve. 2 If r 2If the value of the calibration curve is ≥0.99 (accurate to 2 decimal places), all concentration points under the calibration curve are retained. Otherwise, the concentrations at both ends of the calibration curve are discarded to define influential outliers based on the calculation of the Cook distance, and the outlier concentration points with larger Cook distances are discarded. This process is repeated until the r of the obtained calibration curve is 2 ≥0.99 (accurate to 2 decimal places). Calibration curves of representative standards belonging to each lipid class were plotted and retention times (Rt) were given. The equations of the respective calibration curves were given. LOD was calculated based on the response standard deviation (σ) and slope (S) of the calibration curve, where LOD = 3.3σ / S and LOQ = 10σ / S. r of the calibration curve 2 Round to the nearest two decimal places.

[0065] The results are as follows Figure 2 As shown in Table 1, Figure 2 is the internal standard calibration curve. Table 1 summarizes the limits of detection (LOD) and limits of quantification (LOQ) of various lipids. All calibration curves given in Table 1 include at least six (or more) concentration points, the standard deviation (σ) of the response and the slope (S) of the calibration curve are determined. The limit of detection (LOD) and the limit of quantification (LOQ) are calculated, where LOD=3.3σ / S, LOQ=10σ / S. In Table 1, PC represents phosphatidylcholine lipids, PE represents phosphatidylethanolamine lipids, PG represents phosphatidylglycerol lipids, PI represents phosphatidylinositol lipids, SM represents sphingomyelin lipids, LPC represents lysophosphatidylcholine lipids, LPE represents lysophosphatidylethanolamine lipids, Cer represents ceramide lipids, GluCer represents glucosylceramide lipids, LacCer represents lactosylceramide lipids, Gb3 represents ceramide trihexoside, DAG represents diacylglycerol lipids, and TAG represents triacylglycerol lipids. PC-O indicates alkylated phosphatidylcholine lipids, and CARN indicates acylcarnitine lipids.

[0066] The present invention provides an ultrasensitive lipidomics detection method based on nano-liquid chromatography combined with multiple reaction monitoring (MRMs) under an electrospray ion source (Nano-LC-ESI-MS / MS). The method can detect and quantify lipids at the sub-femtomolar level in a single cell.

[0067] Table 1. LODs and LOQs of lipid classes obtained in single-cell lipidomics approaches

[0068] category Internal standard lipid Rt(min) Calibration curve <![CDATA[r 2 ]]> S σ LOD(fmol) LOQ (fmol) PC <![CDATA[d9-PC32:0(16:0 / 16:0)]]> 9.15 y=-22000+2.5*10^10x 0.99 2.5E+10 110278 0.16 0.48 PC-O <![CDATA[d9-PC36:1p(18:0p / 18:1)]]> 8.93 y=-18000+1.3*10^10x 1.00 1.31E+10 235471 0.61 1.84 PE <![CDATA[d7-PE33:1(15:0 / 18:1)]]> 8.48 y=-1*10^5+2.4*10^10x 1.00 2.4E+10 174898 0.27 0.82 PG <![CDATA[d7-PG33:1(15:0 / 18:1)]]> 8.14 y=540000+4.3*10^9x 1.00 4.33E+09 746685 5.96 18.06 PI <![CDATA[d7-PI33:1(15:0 / 18:1)]]> 8.38 y=760000+8.9*10^9x 0.99 8.91E+09 1E+06 4.22 12.78 SM <![CDATA[d9-SM d18:1 / 18:1]]> 9.30 y=120000+2.2*10^10x 1.00 2.22E+10 468506 0.76 2.29 LPC <![CDATA[d7-LPC18:1]]> 10.7 y=21000+7.3*10^9x 1.00 7.29E+09 84359 0.58 1.75 LPE <![CDATA[d7-LPE18:1]]> 9.10 y=3600+5.2*10^7x 0.99 51827927 6555.8 6.86 20.79 Cer <![CDATA[Cer d18:1-d7 / 15:0]]> 5.30 y=-8900+1.7*10^9x 0.99 1.7E+09 53753 1.57 4.77 GluCer GluCer d18:1 / 8:0 8.05 y=5500+3.1*108x 1.00 3.06E+08 11407 1.68 5.08 LacCer <![CDATA[LacCer-d3(d18:1 / 16:0)]]> 8.55 y=39000+1.8*10^9x 1.00 1.78E+09 101429 1.74 5.27 Gb3 Gb3d18:1 / 17:0 8.85 y=-39000+6.1*10^9x 1.00 6.1E+09 53389 0.22 0.68 CARN <![CDATA[d3-16:0-carnitine]]> 9.28 y=-12000+5.3*10^9x 1.00 5.34E+09 84889 0.96 2.90 DAG <![CDATA[DAG34:0(17:0 / 17:0)-d5]]> 5.33 y=6200+6.3*10^7x 1.00 62945074 1195.2 0.83 2.52 TAG <![CDATA[TAG(14:0)3-d5]]> 5.34 y=1400000+9.1*10^8x 0.99 9.06E+08 1E+06 44.01 133.36

[0069] Example 3: Optimization of stationary phase for nano-liquid chromatography

[0070] Referring to the operating steps of Example 1, the present application also optimizes the ratio of the stationary phase normal phase chromatography column filler and the reverse phase chromatography column filler using the internal standard mixture as the sample to be tested. The optimization results show that ideal test results can be obtained when the mass ratio of the normal phase chromatography column filler and the reverse phase chromatography column filler is in the range of 1:4-2:3. Exemplary results are given: the measurement results when the mass ratios of the normal phase chromatography column filler and the reverse phase chromatography column filler are 1:4, 3:7 and 2:3, respectively. When the mass ratio of the normal phase chromatography column filler and the reverse phase chromatography column filler is 1:4, lipid subclasses such as PC and SM are well separated at different retention times ( Figure 3 When the mass ratio of normal phase column filler to reverse phase column filler is 3:7, lipid subclasses such as PC and SM are well separated at different retention times ( Figure 4 When the mass ratio of normal phase column filler to reverse phase column filler is 2:3, PC and SM lipid subclasses are well separated at different retention times ( Figure 5 ).

[0071] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. A composition for lipid analysis, characterized in that The composition comprises a stationary phase of nano-liquid chromatography, wherein the stationary phase comprises a normal phase chromatography column filler and a reverse phase chromatography column filler, and the mass ratio of the normal phase chromatography column filler to the reverse phase chromatography column filler is 1:4-2:

3.

2. The composition according to claim 1, characterized in that The composition also includes a mobile phase for nano-liquid chromatography, wherein the mobile phase is a mixture of a mobile phase A and a mobile phase B, wherein the mobile phase A is prepared from chloroform, methanol and ammonia water, and the mobile phase B is prepared from chloroform, methanol, water, ammonia water and ammonium acetate solution.

3. The composition according to claim 2, characterized in that The mobile phase A is formed by mixing the following raw materials in parts by volume: 890 parts by volume of chloroform, 100 parts by volume of methanol, and 10 parts by volume of aqueous ammonia; the mobile phase B is formed by mixing the following raw materials in parts by volume: 270 parts by volume of chloroform, 650 parts by volume of methanol, 70 parts by volume of water, 10 parts by volume of aqueous ammonia, and 2 parts by volume of ammonium acetate solution, wherein the ammonium acetate solution is an aqueous solution containing 1M ammonium acetate.

4. The composition according to claim 2 or 3, characterized in that The mobile phase is selected from any one, two or three of the following: A1) the mobile phase is mobile phase 2% B, wherein the mobile phase 2% B is a liquid mixed with 98 parts by volume of mobile phase A and 2 parts by volume of mobile phase B; A2) the mobile phase is mobile phase 55% B, wherein the mobile phase 55% B is a liquid mixed with 45 parts by volume of mobile phase A and 55 parts by volume of mobile phase B; A3) The mobile phase is mobile phase 100% B, and the mobile phase 100% B is 100 parts by volume of mobile phase B.

5. A method for lipid analysis, characterized in that: The method adopts nano-liquid chromatography-tandem mass spectrometry to perform lipid analysis, the analysis method includes nano-liquid chromatography, the stationary phase used in the nano-liquid chromatography includes normal phase chromatography column filler and reverse phase chromatography column filler, and the mass ratio of the normal phase chromatography column filler to the reverse phase chromatography column filler is 1:4-2:

3.

6. The method according to claim 5, characterized in that The nano-liquid chromatography uses the mobile phase described in claim 2, 3 or 4 for gradient elution, and the flow rate of the mobile phase is 800 nL / min. The gradient elution includes the following three steps: The first step of elution: elution was performed for 2 minutes using a mobile phase 2% B, wherein the mobile phase 2% B was a liquid mixed with 98 parts by volume of a mobile phase A and 2 parts by volume of a mobile phase B; The second step of elution: elution was performed for 2 minutes with a mobile phase of 55% B, wherein the mobile phase 55% B was a liquid mixed with 45 parts by volume of mobile phase A and 55 parts by volume of mobile phase B; The third step of elution: elution with mobile phase 100% B for 7.5 minutes, wherein the mobile phase 100% B is 100 parts by volume of mobile phase B; The mobile phase A is formed by mixing the following raw materials in parts by volume: 890 parts by volume of chloroform, 100 parts by volume of methanol, and 10 parts by volume of aqueous ammonia; the mobile phase B is formed by mixing the following raw materials in parts by volume: 270 parts by volume of chloroform, 650 parts by volume of methanol, 70 parts by volume of water, 10 parts by volume of aqueous ammonia, and 2 parts by volume of ammonium acetate solution, wherein the ammonium acetate solution is an aqueous solution containing 1M ammonium acetate.

7. The method according to claim 5 or 6, characterized in that: The samples for the lipid analysis were from single cells.

8. Use of the composition according to any one of claims 1 to 4 in preparing a product for single-cell lipidomics analysis.

9. Use of the composition according to any one of claims 1 to 4 in single cell lipidomics analysis.

10. Use of the method according to any one of claims 5 to 7 in single cell lipidomics analysis.

Citation Information

Patent Citations

  • Separation Of Glycans By Mixed-mode Liquid Chromatography

    CN103877748A

  • Supercritical fluid chromatograph having normal phase and reverse phase and analytic method using the same

    JP2015194363A